Simon Li - SciClone Pharmaceuticals Independent Director
Director
Mr. Simon Li is an Independent Director of SciClone Pharmaceuticals, Inc., since January 2013. Most recently, Mr. Li has served as a Director since January 2013. He is currently the Chairman and Chief Executive Officer of JW Medical System Ltd., an affiliated company of Biosensors International Ltd. From 2006 to 2012, Mr. Li served in various positions at Medtronic, a global medical technology company, including as the Global Officer and Member of the Executive Committee of Medtronic and President, Greater China and Chairman of the Board, MedtronicWeigao JV. Prior to Medtronic, from 1999 to 2005, Mr. Li served in various positions at Johnson Johnson Medical, China including International Vice President, North AsiaNew Business Development, Asia PacificStrategic Medical Affairs, Asia Pacific. Earlier in his career with JJ, he held the positions of International Vice President, North Asia, Managing Director, China and Hong Kong, and Managing Director, China. Prior to JJ, Mr. Li was President and Chief Operating Officer of the ConvaTec business with BristolMyers Squibb in Hong Kong. He also served as General Manager of the pharmaceutical distributor Y.C. Woo Co., Ltd. in Hong Kong. He earned a Bachelor of Arts degree in social sciences from the University of Hong Kong, an M.B.A. degree from Henley Management, and an advanced E.M.B.A. from Harvard Business School. since 2013.
Age | 64 |
Tenure | 11 years |
Professional Marks | MBA |
Phone | 650 358-3456 |
Web | www.sciclone.com |
SciClone Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.16 % which means that it generated a profit of $0.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.19 %, meaning that it created $0.19 on every $100 dollars invested by stockholders. SciClone Pharmaceuticals' management efficiency ratios could be used to measure how well SciClone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.73 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. SciClone Pharmaceuticals has a current ratio of 8.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist SciClone Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, SciClone Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SciClone Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SciClone to invest in growth at high rates of return. When we think about SciClone Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Robert Page | Rave Restaurant Group | 58 | |
Steven Shulman | Ark Restaurants Corp | 76 | |
William Johnson | Biglari Holdings | 71 | |
Arthur Stainman | Ark Restaurants Corp | 75 | |
Guisela Nunez | Ark Restaurants Corp | N/A | |
Marcia Allen | Ark Restaurants Corp | 67 | |
Douglas Schmick | The Cheesecake Factory | 67 | |
William Hammett | Rave Restaurant Group | 71 | |
Laurence Mindel | The Cheesecake Factory | 80 | |
Ramon Phillips | Rave Restaurant Group | 84 | |
Jerome Kransdorf | The Cheesecake Factory | 79 | |
Clinton Coleman | Rave Restaurant Group | 40 | |
Alexander Cappello | The Cheesecake Factory | 62 | |
Herbert Simon | The Cheesecake Factory | 83 | |
Steven Johnson | Rave Restaurant Group | 56 | |
Marilyn Guy | Ark Restaurants Corp | N/A | |
James Mastrian | Biglari Holdings | 76 | |
David Pittaway | The Cheesecake Factory | 66 | |
Vincent Pascal | Ark Restaurants Corp | 81 | |
Kenneth Cooper | Biglari Holdings | 75 | |
Stephen Novick | Ark Restaurants Corp | 77 |
Management Performance
Return On Equity | 0.19 | |||
Return On Asset | 0.16 |
SciClone Pharmaceuticals Leadership Team
Elected by the shareholders, the SciClone Pharmaceuticals' board of directors comprises two types of representatives: SciClone Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SciClone. The board's role is to monitor SciClone Pharmaceuticals' management team and ensure that shareholders' interests are well served. SciClone Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SciClone Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charles Meng, VP of Compliance and General Counsel | ||
Richard Hawkins, Independent Director | ||
Gregg Lapointe, Independent Director | ||
Hong Zhao, CEO of China Operations | ||
Wilson Cheung, CFO, Sr. VP of Fin. and Secretary | ||
Nancy Chang, Director | ||
Anthony Lapointe, Independent Director | ||
Lan Xie, VP of Fin. and CFO of China Operations | ||
Raymond Low, Vice President - Finance, Controller | ||
Robert King, Senior Vice President - Product Development and Supply Chain | ||
Simon Li, Independent Director | ||
Jon Saxe, Independent Chairman of the Board | ||
Friedhelm Blobel, CEO and President Executive Director and Member of Bus. Devel. Committee |
SciClone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SciClone Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.19 | |||
Return On Asset | 0.16 | |||
Profit Margin | 0.21 % | |||
Operating Margin | 25.82 % | |||
Current Valuation | 422 M | |||
Shares Outstanding | 52.19 M | |||
Shares Owned By Insiders | 10.03 % | |||
Shares Owned By Institutions | 79.96 % | |||
Number Of Shares Shorted | 1.21 M | |||
Price To Earning | 13.75 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards SciClone Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, SciClone Pharmaceuticals' short interest history, or implied volatility extrapolated from SciClone Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in SciClone Stock
If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |